Citations

Showing 10 of 108119 citations.

Familial segregation of a 5q15‐q21.2 deletion associated with facial dysmorphism and speech delay
Zepeda‐Mendoza, Cinthya , Goodenberger, McKinsey L. , Kuhl, Ashley , Rice, Gregory M., Hoppman, Nicole L., Hoppman, Nicole, Goodenberger, McKinsey

Mayo Clinic

Clinical Case Reports | May 6, 2019 | Volume: 7 | Issue: 6 | Pages: 1154-1160

10.1002/ccr3.2186 | PMID 31183085 Get It

AbstractWe report a two‐generation family with four females harboring an 8.5Mb heterozygous deletion of 5q15‐q21.2 who present with dysmorphic craniofacial features and speech delay. We hypothesize haploinsufficiency of CHD1 to be contributing to the clinical features observed in this family.
Association of Vital Signs and Process Outcomes in Emergency Department Patients
Hodgson, Nicole R. , Poterack, Karl A. , Mi, Lanyu , Traub, Stephen J.

Mayo Clinic

Western Journal of Emergency Medicine | May 6, 2019 | Volume: 20 | Issue: 3 | Pages: 433-437

10.5811/westjem.2019.1.41498 | PMID 31123542 Get It

DONALD F. RICHARDSON PRIZE PAPERComparing Risk Stratification Criteria for Predicting Lymphatic Dissemination in Endometrial Cancer [06OP]
Kilts, Toni P., Weaver, Amy L. , McGree, Michaela E. , Gostout, Bobbie S., Podratz, Karl C. , Dowdy, Sean C. , Cliby, William A. , Mariani, Andrea , Glaser, Gretchen , Langstraat, Carrie , Kumar, Amanika , Bakkum‐Gamez, Jamie N.

Mayo Clinic

Obstetrics & Gynecology | May 6, 2019 | Volume: 133 | Issue: 1 | Pages: 5-5

10.1097/01.aog.0000559082.68820.f3 Get It

INTRODUCTION: To compare two published risk stratification criteria (Milwaukee Model vs. Mayo Criteria) to predict lymphatic dissemination (LD) in endometrioid endometrial cancer (EC). METHODS: Patients who underwent surgery for EC between 1/1/2004-9/30/2013 and had endometrioid histology without stage IV disease were included and classified as either low-risk or at-risk for LD using two independent risk stratification systems. LD was defined as positive nodes at time of surgery or lymph node recurrence within 2 years of surgery after negative lymph node assessment (LNA) or when LNA was not performed. False positive (FP) and false negative (FN) rates for each risk model were calculated. RESULTS: Among 1103 patients, 81 (7.3%) had LD (72 positive LN and 9 LN recurrences). Most patients (90.2%) had stage I disease. Integration of the Milwaukee Model was associated with a low at-risk rate for LD (38.1%) but a relatively high FN rate (13.6%, 95% CI 7.0-23.0). Conversely, the traditional Mayo Criteria using a tumor diameter (TD) cutoff of ≤2 cm (vs >2 cm) had a higher at-risk rate for LD (69.5%) but a FN rate of 0.0% (95% CI, 0-4.5). Modifying Mayo Criteria using a TD cutoff of ≤3 cm (vs >3 cm) identified fewer women at-risk than using ≤2 cm cutoff (56.8% vs. 69.5%), but had a higher FN rate of 3.7% (95% CI, 0.8-10.4). CONCLUSIONS: The Milwaukee Model had the lowest at-risk rate of LD but an unacceptable FN rate. Modifying the Mayo Criteria by increasing the TD cutoff from the traditional ≤2 cm to ≤3 cm would spare an estimated 12.7% of patients LNA, but the accompanying FN rate is unacceptably high. The traditional Mayo Criteria for low-risk EC remains the most accurate in determining which patients LNA can be omitted.
Influence of Hypertensive Disorders of Pregnancy on Phenotype and Recovery in Peripartum Cardiomyopathy [27L]
Sangtani, Ajleeta , Alrahmani, Layan , Parikh, Pavan

Mayo Clinic

Obstetrics & Gynecology | May 6, 2019 | Volume: 133 | Issue: 1 | Pages: 136S-136S

10.1097/01.aog/01.aog.0000559261.09771.09 Get It

INTRODUCTION: Peripartum cardiomyopathy (PPCM) and cardiomyopathy secondary to hypertensive disorders of pregnancy (HDP) are considered to represent distinct cardiac entities (i.e. dilated vs hypertrophic cardiomyopathy). The goal of this systematic review and meta-analysis was to determine if HDP alters the odds of recovery and if baseline left ventricle characteristics are significantly different. METHODS: Ovid Medline, EMBASE, CENTRAL and Scopus were searched for combinations of the following: hypertension, preeclampsia, cardiomyopathy, peripartum, postpartum or puerperium. Articles describing initial left ventricular ejection fraction (LVEF), odds of recovery (EF >50%) or end diastolic diameter (EDD) amongst those with PPCM were included. Two raters analyzed abstracts and full text to determine eligibility and risk of bias. Risk of bias was determined using the Newcastle-Ottawa scale and the DerSimonian-Laird method was used to combine odds ratios. RESULTS: 1838 articles were identified and 148 full text articles were reviewed for eligibility, with 11 observational studies meeting criteria. There was substantial agreement for selection (K: 0.817) and for risk of bias (K: 0.633) between raters. There was no significant difference (mean: 1.837%, 95% CI-4.882, 1.282) in baseline LVEF or EDD (1.837 cm, 95% CI-1.104, 4.778) between patients who developed PPCM +/- HDP. Further, recovery rates between groups were similar with OR of 1.870 (95% CI 0.854, 4.094) and a moderate degree of heterogeneity. CONCLUSION: Counseling regarding eventual recovery of LVEF after PPCM should not be altered due to the presence of HDP; it is unlikely that a phenotypic difference exists in the cardiomyopathy induced by HDP compared to idiopathic PPCM.
Uterine Leiomyoma With KAT6B-KANSL1 Fusion: Report of a Rapidly Enlarging Uterine Mass in a Postmenopausal Woman [14Q]
Schoolmeester, Kenneth, Ainsworth, Alessandra J. , Bakkum‐Gamez, Jamie N.

Mayo Clinic

Obstetrics & Gynecology | May 6, 2019 | Volume: 133 | Issue: 1 | Pages: 184S-184S

10.1097/01.aog.0000558935.56738.a0 Get It

INTRODUCTION: Leiomyomas are benign uterine smooth muscle tumors. After menopause, most women have a reduction in size and number of leiomyomas. Conversely, uterine sarcomas present as a rapidly enlarging pelvic mass in postmenopausal women. The distinction of uterine leiomyoma from sarcoma is difficult and definitive diagnosis requires pathologic examination. METHODS: A 74 year-old multiparous female with a history of ductal carcinoma in situ (DCIS) of the breast presented with significant postmenopausal bleeding, requiring blood transfusion, and a rapidly enlarging pelvic mass. Abdominal imaging including ultrasound and computerized tomography confirmed a 15 cm uterine mass. The patient underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy with concern for uterine sarcoma. Grossly, the uterus contained a 15.5 cm well demarcated intramural mass. Microscopically, the tumor was a spindle cell neoplasm with anastomosing fascicles interrupted by thick-walled blood vessels or fibrous regions. The cells exhibited uniformly mild to moderate cytologic atypia. Immunohistochemically, the tumor strongly and diffusely expressed desmin and h-caldesmon and exhibited patchy, strong expression of CD10. RNA-seq, confirmed by RT-PCR and Sanger sequencing, revealed a gene fusion involving KAT6B and KANSL1. The fusion joins exon 3 of KAT6B to exons 11 and 12 of KANSL1. The final diagnosis was a benign uterine leiomyoma. The patient remains without evidence of disease six months post-operatively. CONCLUSION: This is the first case, to our knowledge, that has identified the KAT6B-KANSL1 fusion in a uterine leiomyoma. Further efforts to classify the pathologic characteristics and prevalence of this fusion may contribute to understanding of tumorigenesis of uterine smooth muscle tumors.
A Collaborative educational intervention to improve pre-clinical medical student confidence with Advance Care Planning (ACP)
Bp, Verdoorn, Mt, Wingo, Ee, Tung, Verdoorn, Brandon P.

Mayo Clinic

Gerontology & Geriatrics Education | May 6, 2019 | Volume: 42 | Issue: 1 | Pages: 71-81

10.1080/02701960.2019.1611570 | PMID 31056041 Get It

Treatment of stable chronic obstructive pulmonary disease: protocol for a systematic review and evidence map
Dobler, Claudia C. , Farah, Magdoleen H. , Morrow, Allison S. , Alsawas, Mouaz , Benkhadra, Raed, Murad, M. Hassan , Hasan, Bashar , Murad, M Hassan , Alsawas, Mouaz , Hasan, Bashar , Prokop, Larry J. , Wang, Zhen , Farah, Magdoleen H

Mayo Clinic

BMJ Open | May 6, 2019 | Volume: 9 | Issue: 5 | Pages: e027935

10.1136/bmjopen-2018-027935 | PMID 31061055 Get It

Introduction Chronic obstructive pulmonary disease (COPD) is a progressive lung disease, usually caused by tobacco smoking, but other important risk factors include exposures to combustion products of biomass fuels and environmental pollution. The introduction of several new (combination) inhaler therapies, increasing uncertainty about the role of inhaled corticosteroids and a rapid proliferation of the literature on management of stable COPD in general, call for novel ways of evidence synthesis in this area. A systematic review and evidence map can provide the basis for shared decision-making tools and help to establish a future research agenda. Methods and analysis This systematic review will follow an umbrella systematic review design (also called overview of reviews). We plan to conduct a comprehensive literature search of Ovid MEDLINE (including epub ahead of print, in process and other non-indexed citations), Ovid Embase, Ovid Cochrane Database of Systematic Reviews and Scopus from database inception to the present. We will include systematic reviews that assessed the effectiveness of any pharmacological or non-pharmacological intervention on one or more patient-important outcomes and/or lung function in patients with stable COPD. For every intervention/outcome pair, one systematic review will be included. An a priori protocol will guide, which systematic reviews will be chosen, how their credibility will be evaluated, and how the quality of the body of evidence will be rated. Data will be synthesised into an evidence map that will present a matrix that depicts each available treatment for stable COPD with a quantitative estimate on symptoms/outcomes from the patient perspective, along with an indication of the size and certainty in the evidence. Ethics and dissemination Approval by a research ethics committee is not required since the review will only include published data. The systematic review will be published in a peer-reviewed journal. PROSPERO registration number CRD42018095079
Where Will We Draw the Line? Public Opinions of Human Gene Editing
Riggan, Kirsten A. , Sharp, Richard R. , Allyse, Megan , Sharp, Richard R , Allyse, Megan A , Riggan, Kirsten A

Mayo Clinic

Qualitative Health Research | May 6, 2019 | Volume: 29 | Issue: 12 | Pages: 1823-1835

10.1177/1049732319846867 | PMID 31057062 Get It

The application of gene editing technologies to prevent or mitigate genetic disease in humans is considered one of its most promising applications. However, as the technology advances, it is imperative to understand the views of the broader public on how it should be used. We conducted focus groups to understand public views on the ethical permissibility and governance of gene editing technologies in humans. A total of 50 urban and semirural residents in the upper Midwest took part in six focus groups. Participants expressed multiple concerns about nonmedical uses of gene editing and its potential for unknown harms to human health, and were divided as to whether the individual patient or “medical experts” should be charged with overseeing the scope of its application. As potential stakeholders, the perspectives from the general public are critical to assess as genome editing technologies advance toward the clinic.
Patient Perception and Satisfaction With Insulin Pump System: Pilot User Experience Survey
Bayuk, Mike, Karway, George , Corrette, Krystal, Groat, Danielle , Thompson, Bithika , Grando, Maria Adela , Cook, Curtiss B. , Grando, Adela

Mayo Clinic

Journal of Diabetes Science and Technology | May 6, 2019 | Volume: 13 | Issue: 6 | Pages: 1142-1148

10.1177/1932296819843146 | PMID 31055947 Get It

Background: The goal of this study was to assess patient perspectives and satisfaction with the MiniMed 670G insulin pump. Those participants who used the pump as part of a hybrid closed loop were also asked to provide their views on the automatic feature (auto mode). Methods: Adults with type 1 diabetes mellitus using the Medtronic™ 670G pump were asked about their experience with the device using a semi-structured survey developed by the research team. Responses were quantified to identify emergent themes. Results: Seventeen participants used the pump as part of a hybrid closed loop system, while four participants used the pump in combination with a nonintegrated continuous glucose monitoring system. Overall, participants indicated a high level of satisfaction with the pump (14/21) mostly because of improvements in blood glucose (BG) control (15/21). Least liked features were physical design and structure (6/21), frequency of user input (5/21), alert frequency (4/21), and difficulty of use (3/21). Those using the hybrid closed loop were satisfied with the auto mode feature (11/17), mostly because of improvements in BG control (9/17). The least liked features of the auto mode technology were that blood glucose levels remained elevated (5/17) and the frequency of alerts (4/17). Conclusion: Participants indicated a high level of satisfaction with the pump and its auto mode featured mostly because of improvements in BG control. They also pointed out some key aspects of the device that are of potential clinical or commercial relevance. Additional research is needed to further evaluate users' perspectives on this new device.